Report Detail
Global (United States, European Union and China) Duchenne Muscular Dystrophy Drugs Market Research Report 2019-2025
- RnM3715946 |
- 02 September, 2019 |
- Global |
- 147 Pages |
- QYResearch |
- Pharma & Healthcare
Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.
In 2019, the market size of Duchenne Muscular Dystrophy Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Duchenne Muscular Dystrophy Drugs.
This report studies the global market size of Duchenne Muscular Dystrophy Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Duchenne Muscular Dystrophy Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd
Market Segment by Product Type
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
Market Segment by Application
Hospitals and Clinics
Medical Laboratories
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Duchenne Muscular Dystrophy Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Duchenne Muscular Dystrophy Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Development & Drug Target
- 1.3.3 Mechanism of Action (MoA)
- 1.3.4 Route of Administration (RoA)
- 1.3.5 Molecule Type
- 1.4 Market Segment by Application
- 1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2025)
- 1.4.2 Hospitals and Clinics
- 1.4.3 Medical Laboratories
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Duchenne Muscular Dystrophy Drugs Market Size
- 2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2014-2025
- 2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2014-2025
- 2.2 Duchenne Muscular Dystrophy Drugs Growth Rate by Regions
- 2.2.1 Global Duchenne Muscular Dystrophy Drugs Sales by Regions 2014-2019
- 2.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers
- 3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers
- 3.4 Key Manufacturers Duchenne Muscular Dystrophy Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
- 3.6 Key Manufacturers Duchenne Muscular Dystrophy Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Development & Drug Target Sales and Revenue (2014-2019)
- 4.1.2 Mechanism of Action (MoA) Sales and Revenue (2014-2019)
- 4.1.3 Route of Administration (RoA) Sales and Revenue (2014-2019)
- 4.1.4 Molecule Type Sales and Revenue (2014-2019)
- 4.2 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type
- 4.3 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type
- 4.4 Duchenne Muscular Dystrophy Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Duchenne Muscular Dystrophy Drugs Sales by Application
6 United States
- 6.1 United States Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
- 6.2 United States Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
- 6.3 United States Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
- 7.2 European Union Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
- 7.3 European Union Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
8 China
- 8.1 China Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
- 8.2 China Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
- 8.3 China Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
- 9.2 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
- 9.3 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
- 9.4 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Duchenne Muscular Dystrophy Drugs Sales by Countries
- 9.4.2 Rest of World Duchenne Muscular Dystrophy Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Akashi Therapeutics Inc
- 10.1.1 Akashi Therapeutics Inc Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.1.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.1.5 Akashi Therapeutics Inc Recent Development
- 10.2 Antisense Therapeutics Ltd
- 10.2.1 Antisense Therapeutics Ltd Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.2.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.2.5 Antisense Therapeutics Ltd Recent Development
- 10.3 Beech Tree Labs Inc
- 10.3.1 Beech Tree Labs Inc Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.3.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.3.5 Beech Tree Labs Inc Recent Development
- 10.4 Biogen Inc
- 10.4.1 Biogen Inc Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.4.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.4.5 Biogen Inc Recent Development
- 10.5 Bioleaders Corp
- 10.5.1 Bioleaders Corp Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.5.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.5.5 Bioleaders Corp Recent Development
- 10.6 BioMarin Pharmaceutical Inc
- 10.6.1 BioMarin Pharmaceutical Inc Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.6.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.6.5 BioMarin Pharmaceutical Inc Recent Development
- 10.7 Biophytis SAS
- 10.7.1 Biophytis SAS Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.7.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.7.5 Biophytis SAS Recent Development
- 10.8 Capricor Therapeutics Inc
- 10.8.1 Capricor Therapeutics Inc Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.8.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.8.5 Capricor Therapeutics Inc Recent Development
- 10.9 Catabasis Pharmaceuticals Inc
- 10.9.1 Catabasis Pharmaceuticals Inc Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.9.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.9.5 Catabasis Pharmaceuticals Inc Recent Development
- 10.10 CRISPR Therapeutics
- 10.10.1 CRISPR Therapeutics Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
- 10.10.4 Duchenne Muscular Dystrophy Drugs Product Introduction
- 10.10.5 CRISPR Therapeutics Recent Development
- 10.11 Cumberland Pharmaceuticals Inc
- 10.12 Daiichi Sankyo Co Ltd
- 10.13 Debiopharm International SA
- 10.14 Editas Medicine Inc
- 10.15 Eloxx Pharmaceuticals Inc
- 10.16 F. Hoffmann-La Roche Ltd
- 10.17 FibroGen Inc
- 10.18 Fulcrum Therapeutics Inc
- 10.19 Galapagos NV
- 10.20 Genethon SA
- 10.21 GTx Inc
- 10.22 Santhera Pharmaceuticals Holding AG
- 10.23 Sarepta Therapeutics Inc
- 10.24 SOM Biotech SL
- 10.25 Strykagen Corp
- 10.26 Summit Therapeutics Plc
- 10.27 Taiho Pharmaceutical Co Ltd
- 10.28 Teijin Pharma Ltd
- 10.29 WAVE Life Sciences Ltd
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Duchenne Muscular Dystrophy Drugs Sales Channels
- 11.2.2 Duchenne Muscular Dystrophy Drugs Distributors
- 11.3 Duchenne Muscular Dystrophy Drugs Customers
12 Market Forecast
- 12.1 Global Duchenne Muscular Dystrophy Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type
- 12.3 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application
- 12.4 Duchenne Muscular Dystrophy Drugs Forecast by Regions
- 12.4.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Duchenne Muscular Dystrophy Drugs. Industry analysis & Market Report on Duchenne Muscular Dystrophy Drugs is a syndicated market report, published as Global (United States, European Union and China) Duchenne Muscular Dystrophy Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Duchenne Muscular Dystrophy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
